5 Undervalued Biotechnology & Medical Research Stocks for Thursday, December 28
Discover the top 5 undervalued Biotechnology & Medical Research stocks for Thursday, December 28 based on AAII’s Stock Grades.Eunice Kim
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Calidi Biotherapeutics, Inc., a biotechnology company, develops targeted therapies to deliver genetic medicines to distal sites of disease. The company offers CLD-101, which is in Phase 1b/2 clinical trial for the treatment of newly diagnosed high grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast cancer, head and neck cancer, and sarcoma; and CLD-401 for the treatment of metastatic solid tumors. It also offers oncolytic virus platforms, such as NeuroNova and SuperNova. Calidi Biotherapeutics, Inc. was founded in 2014 and is headquartered in San Diego, California.
Commentary & Analysis
3 Undervalued Biotechnology & Medical Research Stocks for Monday, October 16
Discover the top 3 undervalued Biotechnology & Medical Research stocks for Monday, October 16 based on AAII’s Stock Grades.Grace Malone
3 Undervalued Investment Holding Companies Stocks for Thursday, September 14
Discover the top 3 undervalued Investment Holding Companies stocks for Thursday, September 14 based on AAII’s Stock Grades.Pratham Shah
Financial Summary
| Share Statistics | CLDI | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $2.0 | $252.6 | 1% |
|
| Shares Out (Mil) | 0.6 | 52.3 | 3% |
|
| Institutional Ownership | 87.1% | 92.1% | 55% |
|
| Float (Mil) | 1.2 | 40.2 | 3% |
|
| Beta | 1.31 | 0.95 | 76% |
|
| Avg Daily Volume (000s) | 780 | 455 | 66% |
|
| Price Change (52-week) |
(98.7%) | 52.9% | 1% |
|
| Growth | CLDI | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (20.3%) | (9.9%) | 19% |
|
| EPS (5yr) | na | 16.0% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | CLDI | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $38 | na |
|
| Net Income (TTM) (Mil) | ($19) | ($43) | 24% |
|
| EPS (TTM) | ($63.369) | ($1.600) | 1% |
|
| Operating Cash Flow (TTM) (Mil) | ($18) | ($31) | 15% |
|
| Net Cash Flow (TTM) (Mil) | ($4) | $5 | 35% |
|
| Long-Term Debt (Q1) (Mil) | $1 | $5 | 16% |
|
| Enterprise Value (Q1) (Mil) | ($3) | $180 | 3% |
|
| Valuation | CLDI | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.25 | 2.56 | 4% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | CLDI | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 63.8% | na |
|
| Net Margin | na | (67.3%) | na |
|
| ROA | (154.4%) | (49.8%) | 3% |
|
| ROE | (320.4%) | (55.5%) | 2% |
|
| Liabilities to Assets | 48.5% | 30.3% | 40% |
|
| F-Score | 3 | 3 | 19% |
|
Calidi Biotherapeutics, Inc. did not pass any screens on 7/31/2026.
